Clinical significance of p53 alterations in surgically treated prostate cancers.
Standard
Clinical significance of p53 alterations in surgically treated prostate cancers. / Schlomm, Thorsten; Iwers, Liv; Kirstein, Patrick; Jessen, Birte; Köllermann, Jens; Minner, Sarah; Passow-Drolet, Annika; Mirlacher, Martina; Milde-Langosch, Karin; Graefen, Markus; Haese, Alexander; Steuber, Thomas; Simon, Ronald; Huland, Hartwig; Sauter, Guido; Erbersdobler, Andreas.
In: MODERN PATHOL, Vol. 21, No. 11, 11, 2008, p. 1371-1378.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical significance of p53 alterations in surgically treated prostate cancers.
AU - Schlomm, Thorsten
AU - Iwers, Liv
AU - Kirstein, Patrick
AU - Jessen, Birte
AU - Köllermann, Jens
AU - Minner, Sarah
AU - Passow-Drolet, Annika
AU - Mirlacher, Martina
AU - Milde-Langosch, Karin
AU - Graefen, Markus
AU - Haese, Alexander
AU - Steuber, Thomas
AU - Simon, Ronald
AU - Huland, Hartwig
AU - Sauter, Guido
AU - Erbersdobler, Andreas
PY - 2008
Y1 - 2008
N2 - Despite the high number of previous studies, the role of p53 alterations in prostate cancer is not clearly defined. To address the role of p53 alterations in prostate cancer biology, a total of 2514 cancers treated by radical prostatectomy were successfully analyzed by immunohistochemistry in a tissue microarray format. Overall a low rate of p53-positive tumors was found (2.5%). A significant underestimation of p53-positive cases was excluded by subsequent large section analyses and direct sequencing of the p53 gene in subsets of our patients. Large section analysis of 23 cases considered negative on the tissue microarray yielded only one weakly p53-positive tumor. Only 4 out of 64 (6.4%) high-grade tumors, that were considered negative for p53 by immunohistochemistry, presented exon 5-8 mutations. These data suggest a high sensitivity of our immunohistochemistry approach and confirm the overall low frequency of p53 alterations in clinically localized prostate cancer. A positive p53 immunostaining was strongly associated with presence of exon 5-8 mutations (P
AB - Despite the high number of previous studies, the role of p53 alterations in prostate cancer is not clearly defined. To address the role of p53 alterations in prostate cancer biology, a total of 2514 cancers treated by radical prostatectomy were successfully analyzed by immunohistochemistry in a tissue microarray format. Overall a low rate of p53-positive tumors was found (2.5%). A significant underestimation of p53-positive cases was excluded by subsequent large section analyses and direct sequencing of the p53 gene in subsets of our patients. Large section analysis of 23 cases considered negative on the tissue microarray yielded only one weakly p53-positive tumor. Only 4 out of 64 (6.4%) high-grade tumors, that were considered negative for p53 by immunohistochemistry, presented exon 5-8 mutations. These data suggest a high sensitivity of our immunohistochemistry approach and confirm the overall low frequency of p53 alterations in clinically localized prostate cancer. A positive p53 immunostaining was strongly associated with presence of exon 5-8 mutations (P
M3 - SCORING: Zeitschriftenaufsatz
VL - 21
SP - 1371
EP - 1378
JO - MODERN PATHOL
JF - MODERN PATHOL
SN - 0893-3952
IS - 11
M1 - 11
ER -
